116 related articles for article (PubMed ID: 32932545)
41. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
Urquhart A; Berg R
Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
43. Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study.
Frison L; Lombardi A; Caputo I; Semenzato G; Fabris F; Vianello F
Hematology; 2019 Dec; 24(1):134-138. PubMed ID: 30355275
[TBL] [Abstract][Full Text] [Related]
44. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
45. Clinical characteristics of and response to combination chemotherapy and subsequent application of international prognostic index in non-Hodgkin's lymphoma--an experience from a medical center in Southern Taiwan.
Hsieh CI; Su WC; Chien CH; Cuo YL; Chen TY; Kao RH; Tsao CJ
Kaohsiung J Med Sci; 1996 Feb; 12(2):69-82. PubMed ID: 8709176
[TBL] [Abstract][Full Text] [Related]
46. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
47. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.
Kearon C; Parpia S; Spencer FA; Baglin T; Stevens SM; Bauer KA; Lentz SR; Kessler CM; Douketis JD; Moll S; Kaatz S; Schulman S; Connors JM; Ginsberg JS; Spadafora L; Bhagirath V; Liaw PC; Weitz JI; Julian JA
Blood; 2018 May; 131(19):2151-2160. PubMed ID: 29490924
[TBL] [Abstract][Full Text] [Related]
48. Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience.
Tondini C; Giardini R; Bozzetti F; Valagussa P; Santoro A; Bertulli R; Balzarotti M; Rocca A; Lombardi F; Ferreri AJ
Ann Oncol; 1993 Dec; 4(10):831-7. PubMed ID: 8117602
[TBL] [Abstract][Full Text] [Related]
49. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
50. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
[TBL] [Abstract][Full Text] [Related]
51. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
52. A controversial issue: could a watch-and-wait policy for patients with non-Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery be justified? Results of a single centre study.
Jelić S; Frim O; Gligorijević G; Gavrilović D; Manojlović N; Jovanović V; Oprić M
Hematol Oncol; 1997 May; 15(2):53-61. PubMed ID: 9375030
[TBL] [Abstract][Full Text] [Related]
53. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
Papageorgiou A; Ziogas DC; Mavragani CP; Zintzaras E; Tzioufas AG; Moutsopoulos HM; Voulgarelis M
PLoS One; 2015; 10(2):e0116189. PubMed ID: 25723713
[TBL] [Abstract][Full Text] [Related]
54. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Portlock CS; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz AD; O'Brien JP; Moskowitz C; Norton L; Yahalom J; Straus DJ; Bertino JR
Ann Oncol; 2004 Oct; 15(10):1495-503. PubMed ID: 15367410
[TBL] [Abstract][Full Text] [Related]
55. Novel enzyme immunoassay system for simultaneous detection of six subclasses of antiphospholipid antibodies for differential diagnosis of antiphospholipid syndrome.
Nojima J; Motoki Y; Hara K; Sakata T; Ichihara K
Blood Coagul Fibrinolysis; 2017 Jun; 28(4):316-322. PubMed ID: 27676644
[TBL] [Abstract][Full Text] [Related]
56. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.
Uskudar Teke H; Gulbas Z; Bal C
J BUON; 2014; 19(1):191-7. PubMed ID: 24659663
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.
Manohar K; Mittal BR; Bhattacharya A; Malhotra P; Varma S
Nucl Med Commun; 2012 Sep; 33(9):974-81. PubMed ID: 22811258
[TBL] [Abstract][Full Text] [Related]
58. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
59. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
Gómez H; Hidalgo M; Casanova L; Colomer R; Pen DL; Otero J; Rodríguez W; Carracedo C; Cortés-Funes H; Vallejos C
J Clin Oncol; 1998 Jun; 16(6):2065-9. PubMed ID: 9626205
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy.
Alici S; Bavbek S; Basaran M; Onat H
Adv Ther; 2006; 23(4):534-42. PubMed ID: 17050496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
